HC Wainwright Reiterates Buy Rating for Senseonics (NYSE:SENS)

HC Wainwright reaffirmed their buy rating on shares of Senseonics (NYSE:SENS) in a report published on Friday,Benzinga reports. They currently have a $2.00 price target on the stock.

Separately, StockNews.com started coverage on Senseonics in a research note on Friday, November 8th. They issued a “sell” rating for the company.

Senseonics Stock Performance

Senseonics stock opened at $0.28 on Friday. The stock has a market cap of $167.77 million, a PE ratio of -2.18 and a beta of 0.79. The company has a quick ratio of 2.89, a current ratio of 2.47 and a debt-to-equity ratio of 59.17. Senseonics has a 12-month low of $0.28 and a 12-month high of $0.75. The business’s 50-day moving average price is $0.35 and its two-hundred day moving average price is $0.40.

Hedge Funds Weigh In On Senseonics

A number of hedge funds have recently modified their holdings of the business. FMR LLC increased its holdings in Senseonics by 48,267.2% in the third quarter. FMR LLC now owns 168,318 shares of the company’s stock valued at $59,000 after purchasing an additional 167,970 shares during the period. State Board of Administration of Florida Retirement System acquired a new stake in shares of Senseonics in the first quarter valued at about $91,000. GSA Capital Partners LLP bought a new position in shares of Senseonics during the third quarter worth about $117,000. Virtu Financial LLC acquired a new position in shares of Senseonics in the first quarter worth approximately $162,000. Finally, Symmetry Partners LLC bought a new stake in Senseonics in the third quarter valued at approximately $164,000. Institutional investors and hedge funds own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.